



#33  
IDS w/attach  
52.03  
PATENT

Customer No. 22,852  
Attorney Docket No. 3495.0010-12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc ALIZON et al.

Application No.: 08/026,736

Filed: March 5, 1993

)  
)  
) Group Art Unit: 1648  
)  
) Examiner: PARKIN, Jeffrey  
)  
)  
)

TECH CENTER 1600/2900

APR 25 2003

RECEIVED

For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF  
LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS  
ENCODED BY SAID LAV GENOMIC RNA

Commissioner for Patents  
Washington, DC 20231

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed documents are enclosed.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

04/24/2003 NMOHAMM 00000027 09026736

01 FC:1806

180.00 0P

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 23, 2003

By: \_\_\_\_\_

  
Salvatore J. Arrigo  
Reg. No. 46,063

Telephone: 202-408-4160

Facsimile: 202-408-4400

E-mail: [arrigos@finnegan.com](mailto:arrigos@finnegan.com)

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)